In 2021, IRE will celebrate its 50th anniversary. Half a century of innovations at the service of health and nuclear medicine.
1971 - 1973
Creation of IRE and first constructions.
1973 - 1978
First transfer of activities to Fleurus.
Construction of six buildings in record times.
First production runs of 131I and 99Mo.
Creation of a radioimmunology department.
Creation of a 60Co irradiation treatment unit.
Sterilization of medical equipment.
First production of 123I.
1978 - 1991
Creation of the production unit of 192Ir, for sealed sources.
Construction of the first cyclotron.
Pharmaceutical approval of the company.
Creation of molecules marked with tritium and 14C.
Production of tritiated thymidine.
Production of 85Kr fire detectors.
Production of 60Co discs.
Production of 192Ir industrial radiography equipment.
Development of injectable radioactive preparations based on 59Fe, 47Ca, 197Hg and 85Sr, as well as 192Ir sutures and pins (brachytherapy).
Creation of the concept for a repetitive elution 99mTc dry generator.
Creation of the transport subsidiary company TRANSRAD.
1991 - 2008
Impact of Regionalization on some of the IRE’s activities:
Sale of the radiopharmaceutical product lines to the NORDION group.
Divestment of the sterilization and radioimmunology testing activities.
Refocusing of the IRE activity on the core businesses with the production of the medical radioisotopes 99Mo, 131I and 133Xe.
Major investments in the context of the redeployment of radiopharmaceutical activities.
Development of equipment for the remote monitoring of environmental radioactivity and radiological monitoring missions within the territory.
Support by IRE of the development of the company IBA, which also invested in the Fleurus site (R&D activities supported by a prototype 14 MeV SE cyclotron).
2008 - 2010
Important expansion of international commercial activities. In addition to the European market, IRE takes a significant role as a major stakeholder in North America, Asia, and the Middle East. This achievement provided IRE with a leadership position in the production of 99Mo and 131I.
Substantial investments in the renovation of installations in terms of safety, security and quality.
Creation of the IRE ELiT subsidiary.
New development in radiopharmaceutical activities in the diagnostic and therapy sectors (90Y, 188Re, 68Ga, etc.).
Major consultancy contracts worldwide (European Commission, IAEA, etc.).
2010 - 2015
New IRE communication policy in relation to its environment.
Growth in revenue from 2010 to 2015: 140%.
Growth in headcount from 2010 to 2015: 53%.
Launch of research partnerships worldwide.
First partnership with Belgian universities in the field of medical research.
Major participation in the NEA/OECD High-Level Group (HLG) on the Security of Supply of Medical Radioisotopes.
Important IRE role in AIPES (Association of Imaging Producers & Equipment Suppliers).
Participation in the BioWin Health Cluster of the Walloon region (southern part of Belgium).
IRE ELiT launches Galli Eo (a Germanium-68/Gallium-68 generator) on the market, a major and totally innovative advance in the field of cancer imaging.
IRE announces a partnership with the company ASML, with the aim of developing a new method for the production of medical isotopes, without fission, such as Mo-99/Tc-99m. This is the beginning of the SMART project.
IRE and SCK CEN announce the signature of a Public-Public Partnership called RECUMO which provides a structural solution to manage the residues from the production of medical radioisotopes stored on the IRE site in Fleurus.
IRE ELiT takes a key step in the conquest of the radiopharmaceuticals market and obtains marketing authorisation in Europe for its Gallium-68 generator, which will henceforth be called Galli Ad on this territory.
The first transport of irradiated material was made from Fleurus to Mol. This transport is part of the public-public partnership between the IRE and SCK CEN.
IRE ELiT's Service Business Unit officially launched RAMSES, the first automatic real-time radiological monitoring system, on the market at the SFRP congress.
IRE officialises the acquisition of the activities of the Service Business Unit of its subsidiary IRE ELiT. The Business Unit Service is now called IRE Lab.
IRE ELiT and Isologic announce the approval of Gallium-68's generator, Galli Eo®, as a drug in Canada.
IRE and SCK CEN research centre sign a public-public partnership with the initial aim of producing the radioisotope lutetium-177 (Lu-177).
IRE ELiT extends its product range by launching a generator dedicated to pre-clinical research, Galli RD, on the world market.